Skip Navigation
Search Menu
Find a Doctor

 

Photo of Dr. Arlene Forastiere

Arlene Forastiere, M.D.

Female

Appointment Phone

410-955-8964

Main Location

The Johns Hopkins Hospital

Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-7683 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Departments

  • Oncology

Locations

The Johns Hopkins Hospital

Appointment Phone: 410-955-8964

600 N. Wolfe Street
Sheikh Zayed Tower
Baltimore, MD 21287 map

The Johns Hopkins Hospital

600 N. Wolfe Street
Carnegie 446D1
Baltimore, MD 21287 map

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964

401 N. Broadway
Baltimore, MD 21231 map

Expertise

Medical Oncology

Research Interests

Head and neck cancer, esophageal cancer

    Additional Information

  • Education +

    Degrees

    • New York Medical College / MD (1975)

    Certifications

    • American Board of Internal Medicine / Internal Medicine (1978)
    • American Board of Internal Medicine / Medical Oncology (1981)
  • Research & Publications +

    Selected Publications

    Forastiere, A.A.; Trotti, A.; Pfister, D.G.; Grandis, J.R. Head and neck cancer: recent advances and new standards of care. J Clin Oncol. 2006 Jun 10;24(17):2603-2605.
    Gibson, M.K.; Forastiere, A.A. Reassessment of the role of induction chemotherapy for head and neck cancer. Lancet Oncol. 2006 Jul;7(7):565-574.
    Gilbert, J.; Li, Y.; Pinto, H.A.; Jennings, T.; Kies, M.S.; Silverman, P.; Forastiere, A.A. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck. 2006 Mar;28(3):197-204.
    Heath, E.I.; Burtness, B.A.; Kleinberg, L.; Salem, R.R.; Yang, S.C.; Heitmiller, R.F.; Canto, M.I.; Knisely, J.P.; Topazian, M.; Montgomery, E.; Tsottles, N.; Pithavala, Y.; Rohmiller, B.; Collier, M.; Forastiere, A.A. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Invest New Drugs. 2006 Mar;24(2):135-140.
    Jimeno, A.; Kulesza, P.; Kincaid, E.; Bouaroud, N.; Chan, A.; Forastiere, A.; Brahmer, J.; Clark, D.P.; Hidalgo, M. C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer Res. 2006 Feb 15;66(4):2385-2390.
    Kleinberg, L.; Gibson, M.; Yang, S.; Forastiere, A.A.; Putnam, J.B. Primary Combined Modality Therapy for Esophageal Cancer. Oncology. 2006;20(5):505-511.
    Montgomery, E.; Mamelak, A.J.; Gibson, M.; Maitra, A.; Sheikh, S.; Amr, S.S.; Yang, S.; Brock, M.; Forastiere, A.; Zhang, S.; Murphy, K.M.; Berg, K.D. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions. Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):24-30.
    Pfister, D.G.; Laurie, S.A.; Weinstein, G.S.; Mendenhall, W.M.; Adelstein, D.J.; Ang, K.K.; Clayman, G.L.; Fisher, S.G.; Forastiere, A.A.; Harrison, L.B.; Lefebvre, J.L.; Leupold, N.; List, M.A.; O''Malley, B.O.; Patel, S.; Posner, M.R.; Schwartz, M.A.; Wolf, G.T. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006 Aug 1;24(22):3693-3704.
    Cmelak, A.J.; Li, S.; Goldwasser, M.A.; Murphy, B.; Cannon, M.; Pinto, H.; Rosenthal, D.I.; Gillison, M.; Forastiere, A.A. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol. 2007 Sep 1;25(25):3971-3977.
    Forastiere, A.A.; Burtness, B.A. Epidermal growth factor receptor inhibition in head and neck cancer-more insights, but more questions. J Clin Oncol. 2007 Jun 1;25(16):2152-2155.
    Heath, E.I.; Canto, M.I.; Piantadosi, S.; Montgomery, E.; Weinstein, W.M.; Herman, J.G.; Dannenberg, A.J.; Yang, V.W.; Shar, A.O.; Hawk, E.; Forastiere, A.A. Secondary chemoprevention of Barrett''s esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007 Apr 4;99(7):545-557.
    Jimeno, A.; Kulesza, P.; Wheelhouse, J.; Chan, A.; Zhang, X.; Kincaid, E.; Chen, R.; Clark, D.P.; Forastiere, A.; Hidalgo, M. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer. 2007 Mar 26;96(6):952-959.
    Kleinberg, L.; Forastiere, A.A. Chemoradiation in the management of esophageal cancer. J Clin Oncol. 2007 Sep 10;25(26):4110-4117.
    Kleinberg, L.; Gibson, M.K.; Forastiere, A.A. Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization. Nature clinical practice. 2007 May;4(5):282-294.
    Poeta, M.L.; Manola, J.; Goldwasser, M.A.; Forastiere, A.; Benoit, N.; Califano, J.A.; Ridge, J.A.; Goodwin, J.; Kenady, D.; Saunders, J.; Westra, W.; Sidransky, D.; Koch, W.M. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007 Dec 20;357(25):2552-2561.
    Trotti, A.; Pajak, T.F.; Gwede, C.K.; Paulus, R.; Cooper, J.; Forastiere, A.; Ridge, J.A.; Watkins-Bruner, D.; Garden, A.S.; Ang, K.K.; Curran, W. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol. 2007 Jul;8(7):613-624.
    Burtness, B.A.; Manola, J.; Axelrod, R.; Argiris, A.; Forastiere, A.A. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008 May;19(5):977-983.
    Cohen, E.E.; Rosen, L.S.; Vokes, E.E.; Kies, M.S.; Forastiere, A.A.; Worden, F.P.; Kane, M.A.; Sherman, E.; Kim, S.; Bycott, P.; Tortorici, M.; Shalinsky, D.R.; Liau, K.F.; Cohen, R.B. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10;26(29):4708-4713.
    el-Shami, K.; Forastiere, A.A. Head and Neck Cancer. In: Ettinger, D., et al, editor. 5th Edition ed, Current Cancer Therapeutics. New York, NY: Churchill-Livingstone; 2008.
    Fakhry, C.; Westra, W.H.; Li, S.; Cmelak, A.; Ridge, J.A.; Pinto, H.; Forastiere, A.; Gillison, M.L. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008 Feb 20;100(4):261-269.
    Forastiere, A.; Weber, R.; Ang, K. Treatment of head and neck cancer. N Engl J Med. 2008 Mar 6;358(10):1076; author reply 1077-1078.
    Forastiere, A.A. Chemotherapy in the treatment of locally advanced head and neck cancer. J Surg Oncol. 2008 Jun 15;97(8):701-707.
    Forastiere, A.A.; Ang, K.K.; Brizel, D.; Brockstein, B.E.; Burtness, B.A.; Cmelak, A.J.; Colevas, A.D.; Dunphy, F.; Eisele, D.W.; Goepfert, H.; Hicks, W.L., Jr.; Kies, M.S.; Lydiatt, W.M.; Maghami, E.; Martins, R.; McCaffrey, T.; Mittal, B.B.; Pfister, D.G.; Pinto, H.A.; Posner, M.R.; Ridge, J.A.; Samant, S.; Schuller, D.E.; Shah, J.P.; Spencer, S.; Trotti, A., 3rd; Weber, R.S.; Wolf, G.T.; Worden, F. Head and neck cancers. J Natl Compr Canc Netw. 2008 Aug;6(7):646-695.
    Garden, A.S.; Harris, J.; Trotti, A.; Jones, C.U.; Carrascosa, L.; Cheng, J.D.; Spencer, S.S.; Forastiere, A.; Weber, R.S.; Ang, K.K. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1351-1355.
    Giantonio, B.J.; Forastiere, A.A.; Comis, R.L. The role of the Eastern Cooperative Oncology Group in establishing standards of cancer care: over 50 years of progress through clinical research. Semin Oncol. 2008 Oct;35(5):494-506.
    Juergens, R.A.; Forastiere, A. Combined modality therapy of esophageal cancer. J Natl Compr Canc Netw. 2008 Oct;6(9):851-860; quiz 861.
    Kleinberg, L.R.; Brock, M.V.; Jagannath, S.B.; Forastiere, A.A. Cancer of the Esophagus. In: Abeloff, M.e.a., editor. 4th Edition ed, Clinical Oncology. New York, NY: Churchill-Livingstone; 2008.
    Machtay, M.; Moughan, J.; Trotti, A.; Garden, A.S.; Weber, R.S.; Cooper, J.S.; Forastiere, A.; Ang, K.K. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008 Jul 20;26(21):3582-3589.
    Marur, S.; Forastiere, A.A. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008 Apr;83(4):489-501.
    Sanguineti, G.; Forastiere, A.A. Determining the survival benefit of adjuvant radiotherapy in patients with node-positive head and neck cancer. Nature clinical practice. 2008 Dec;5(12):694-695.
    Shar, A.O.; Gaudard, M.A.; Heath, E.I.; Forastiere, A.A.; Yang, V.W.; Sontag, S.J. Quantitative endoscopy in the chemoprevention of Barrett''s Esophagus Trial. Dis Esophagus. 2008;21(7):641-644.
    Yoon, H.H.; Forastiere, A.A. Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome. Future oncology (London, England). 2008 Jun;4(3):413-425.
    Adelstein, D.J.; Ridge, J.A.; Gillison, M.L.; Chaturvedi, A.K.; D''Souza, G.; Gravitt, P.E.; Westra, W.; Psyrri, A.; Kast, W.M.; Koutsky, L.A.; Giuliano, A.; Krosnick, S.; Trotti, A.; Schuller, D.E.; Forastiere, A.; Ullmann, C.D. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck. 2009 Nov;31(11):1393-1422.
    Argiris, A.; Buchanan, A.; Brockstein, B.; Kolesar, J.; Ghebremichael, M.; Pins, M.; Hahn, K.; Axelrod, R.; Forastiere, A. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer. 2009 Oct 1;115(19):4504-4513.
    Burtness, B.; Gibson, M.; Egleston, B.; Mehra, R.; Thomas, L.; Sipples, R.; Quintanilla, M.; Lacy, J.; Watkins, S.; Murren, J.R.; Forastiere, A.A. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol. 2009 Jul;20(7):1242-1248.
    El-Naggar, A.K.; Kaye, F.J.; Shirazi, Y.; Gutkind, J.S.; Forastiere, A.A. Meeting report-the NIDCR 2(nd) Salivary Gland Tumor Meeting, November 2008. Head Neck. 2009 Dec;31(12):1542-1543.
    Forastiere, A.A.; Marur, S. Head and Neck Cancer. In: Moore, A., editor. 4th Edition ed, ASCO Medical Oncology Self-Evaluation Program. Alexandria, VA: American Society of Clinical Oncology; 2009.
    Forastiere, A.A.; Shaha, A.R. Chemotherapy alone for laryngeal preservation-is it possible? J Clin Oncol. 2009 Apr 20;27(12):1933-1934.
    Forastiere, A.A.; Trotti, A.M. Searching for less toxic larynx preservation: a need for common definitions and metrics. J Natl Cancer Inst. 2009 Feb 4;101(3):129-131.
    Higgins, M.J.; Forastiere, A.; Marur, S. New directions in the systemic treatment of metastatic thyroid cancer. Oncology. 2009;23(9):768-775.
    Koch, W.M.; Ridge, J.A.; Forastiere, A.; Manola, J. Comparison of clinical and pathological staging in head and neck squamous cell carcinoma: results from Intergroup Study ECOG 4393/RTOG 9614. Arch Otolaryngol Head Neck Surg. 2009 Sep;135(9):851-858.
    Meguid, R.A.; Hooker, C.M.; Taylor, J.T.; Kleinberg, L.R.; Cattaneo, S.M., 2nd; Sussman, M.S.; Yang, S.C.; Heitmiller, R.F.; Forastiere, A.A.; Brock, M.V. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response? J Thorac Cardiovasc Surg. 2009 Dec;138(6):1309-1317.
    Poeta, M.L.; Manola, J.; Goldenberg, D.; Forastiere, A.; Califano, J.A.; Ridge, J.A.; Goodwin, J.; Kenady, D.; Saunders, J.; Westra, W.; Sidransky, D.; Koch, W.M. The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins. Clin Cancer Res. 2009 Dec 15;15(24):7658-7665.
    Rosenthal, D.I.; Harris, J.; Forastiere, A.A.; Weber, R.S.; Ridge, J.A.; Myers, J.N.; Garden, A.S.; Kuettel, M.R.; Sidhu, K.; Schultz, C.J.; Trotti, A.; Ang, K.K. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol. 2009 Oct 1;27(28):4727-4732.
    Sanguineti, G.; Califano, J.; Stafford, E.; Fox, J.; Koch, W.; Tufano, R.; Sormani, M.P.; Forastiere, A. Defining the Risk of Involvement for Each Neck Nodal Level in Patients With Early T-Stage Node-Positive Oropharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2009 Jan 6.
    Shar, A.O.; Gaudard, M.A.; Heath, E.I.; Forastiere, A.A.; Yang, V.W.; Sontag, S.J. Modeling using baseline characteristics in a small multicenter clinical trial for Barrett''s esophagus. Contemporary clinical trials. 2009 Jan;30(1):2-7.
    Wee, J.T.; Anderson, B.O.; Corry, J.; D''Cruz, A.; Soo, K.C.; Qian, C.N.; Chua, D.T.; Hicks, R.J.; Goh, C.H.; Khoo, J.B.; Ong, S.C.; Forastiere, A.A.; Chan, A.T. Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009 Nov;10(11):1086-1092.
    Altiok, S.; Mezzadra, H.; Jagannath, S.; Tsottles, N.; Rudek, M.A.; Abdallah, N.; Berman, D.; Forastiere, A.; Gibson, M.K. A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. Int J Oncol. 2010 Jan;36(1):19-27.
    Chung, C.H.; Seeley, E.H.; Roder, H.; Grigorieva, J.; Tsypin, M.; Roder, J.; Burtness, B.A.; Argiris, A.; Forastiere, A.A.; Gilbert, J.; Murphy, B.; Caprioli, R.M.; Carbone, D.P.; Cohen, E.E. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):358-365.
    Forastiere, A.A. Larynx preservation and survival trends: should there be concern? Head Neck. 2010 Jan;32(1):14-17.
    Forastiere, A.A.; Marur, S. Head and Neck Cancer. Second Edition ed, ASCO-Sep: Medical Oncology Self-Evaluation Program; 2010.
    Gourin, C.G.; Tufano, R.P.; Forastiere, A.A.; Koch, W.M.; Pawlik, T.M.; Bristow, R.E. Volume-based trends in thyroid surgery. Arch Otolaryngol Head Neck Surg. 2010 Dec;136(12):1191-1198.
    Konski, A.; Bhargavan, M.; Owen, J.; Paulus, R.; Cooper, J.; Forastiere, A.; Ang, K.K.; Watkins-Bruner, D. Feasibility of Economic Analysis of Radiation Therapy Oncology Group (RTOG) 91-11 using Medicare Data. Int J Radiat Oncol Biol Phys. 2010 May 14;79(2):436-442.
    Marur, S.; D''Souza, G.; Westra, W.H.; Forastiere, A.A. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010 Aug;11(8):781-789.
    Marur, S.; Forastiere, A.A. Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer. Curr Opin Oncol. 2010 May;22(3):206-211.
    Quon, H.; Leong, T.; Haselow, R.; Leipzig, B.; Cooper, J.; Forastiere, A. Phase III Study of Radiation Therapy With or Without Cis-Platinum in Patients with Unresectable Squamous or Undifferentiated Carcinoma of the Head and Neck: An Intergroup Trial of the Eastern Cooperative Oncology Group (E2382). Int J Radiat Oncol Biol Phys. 2010 Sep 30;Epub ahead of print.
  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
Is This You? Edit Profile